HIV integrase as a target for antiretroviral therapy

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 383-389

  Hazuda, Daria J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

antiretrovirals; InSTIs; integrase

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; NUCLEOPHILE; RALTEGRAVIR; VIRUS DNA;

ANTIRETROVIRAL THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHEMICAL ANALYSIS; CHEMOPROPHYLAXIS; CHROMOSOME; CLINICAL PRACTICE; CRYSTAL STRUCTURE; DNA BINDING; DNA STRAND; DRUG MECHANISM; DRUG STRUCTURE; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84865663948     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283567309     Document Type: Review

References (33)

1. Lewinski MK, Bushman FD. Retroviral DNA integration - mechanism and consequences. Adv Genet 2005; 55:147-181.
2. Engelman A. Reverse transcription and integration. In: Kurth R, Bannert N, editors. Retroviruses: molecular biology, genomics and pathogenesis. Norfolk, United Kingdom: Caister Academic Press; 2010. pp. 129-159.
3. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: Effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995; 69:376-386.
4. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004; 4:965-977.
5. Christ F, Voet A, Marchand A, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010; 6:442-448
6. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr Top Med Chem 2004; 4:1059- 1077.
7. Hazuda DJ, Felock PJ, Hastings JC, et al. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J Virol 1997; 71:7005-7011.
8. Hazuda DJ, Hastings JC,Wolfe AL,Emini EA. A novel assay for theDNA strandtransfer reaction of HIV-1 integrase. Nucleic Acids Res 1994; 22:1121-1122
9. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646- 650
10. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000; 97:11244-11249
11. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV- AIDS infection. J Med Chem 2008; 51:5843-5855.
12. Shimura K, Kodama EN. Elvitegravir: A new HIV integrase inhibitor. Antivir Chem Chemother 2009; 20:79-85.
13. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572; a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813-821.
14. Hicks C, Gulick RM. Raltegravir: The first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931-939.
15. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464:232-236
16. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002; 99:6661-6666
17. Koh Y, Matreyek KA, Engelman, A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J Virol 2011; 85:3677
18. Hare S, Vos AM, Clayton RF, et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010; 107:20057-20062
19. Métifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses 2010; 2:1347-1366.
20. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008; 22:1877-1880.
21. Low A, Prada N, Topper M, et al. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009; 53:4275-4282.
22. Stevenson MT, Stanwick L, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9:1551-1560.
23. Buzón M, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
24. Vatakis DN, Nixon CC, Bristol G, Zack JA. Differentially stimulated CD4-cells display altered human immunodeficiency virus infection kinetics: Implications for the efficacy of antiviral agents. J Virol 2009; 83:3374-3378.
25. Grobler JA, McKenna PM, Ly S, et al. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors. 10th International Workshop on Clinical Pharmacology of HIV Therapy. 2009; Abstract O-10.
26. Koh Y, Haim H, Engelman A. Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity. Antimicrob Agents Chemother 2011; 55:42-49.
27. Grobler JA, Stillmock KA, Hazuda DJ. Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. Methods 2009; 47:249-253.
28. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-2321.
29. Andrade A, Rosenkranz S, Daar E, et al., for the ACTG 5248. Longer phase viral decay in treatment-nai=ve patients receiving raltegravir-based ART preliminary results from ACTG 5248 CROI 2010 Abstract 263
30. Andrade A, Rosenkranz S, Cillo A, et al., the ACTG 5248 Team. Three phases of plasma HIV-1 RNA decay revealed by single-copy assay in ARV-naíve patients initiating ART with raltegravir, tenofovir, and emtricitabine: ACTG A5248. CROI; 2012; Abstract 672.
31. Eron J, Cooper DA, Steigbigel RT, et al., for the BENCHMRK-1 and 2 Study Groups. Exploratory analysis in the BENCHMRK studies at week 192: Late outcomes based on early virologic responses. IAS 2011; Abstract MOPE2225.
32. Neff CP, Ndolo T, Tandon A, et al. Oral preexposure prophylaxis by antiretrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010; 5:15257.
33. Dobard C, Sharma S, Parikh U, et al. High protection against vaginal infection in Macaques by PEP with gel containing RAL. CROI; 2011; Abstract 30.